Results 111 to 120 of about 17,638 (200)

Phase I and pharmacologic study of topotecan in patients with impaired renal function.

, 1996
PURPOSE To determine the toxicities, pharmacokinetics, and recommended doses of the topoisomerase I inhibitor, topotecan, in patients with varying degrees of renal excretory dysfunction.
A A Forastiere, S O'Reilly, T L Chen, L B Grochow, D S Ettinger, S Sartorius, E K Rowinsky, W Slichenmyer, R C Donehower   +8 more
core   +1 more source

Phase I Pharmacologic Study of Oral Topotecan and Intravenous Cisplatin: Sequence-Dependent Hematologic Side Effects

, 2000
PURPOSE: In in vitro studies, synergism and sequence-dependent effects were reported for the combination of topotecan and cisplatin. Recently, an oral formulation of topotecan became available.
Walter J. Loos, Jaap Verweij, Eddie Doyle, Hans Gelderblom, André S. Th. Planting, Marijke A. Mantel, Graham Ross, Solange Hearn, Eric Brouwer, Vera van Beurden, Maja J. A. de Jonge, Maria E. L. van der Burg, Alex Sparreboom   +12 more
core   +1 more source

Andrographolide potentiates the antitumor effect of topotecan in acute myeloid leukemia cells through an intrinsic apoptotic pathway

, 2018
Mohammad Hassan Hodroj, Achraf Jardaly, Sarah Abi Raad, Annalise Zouein, Sandra Rizk Department of Natural Sciences, Lebanese American University, Beirut, Lebanon Background: Topotecan (TP) is an anticancer drug acting as topoisomerase I inhibitor that ...
Abi Raad S, Rizk S, Jardaly A, Hodroj MH, Zouein A   +4 more
core  

A study of variable hydration states in topotecan hydrochloride

, 2006
Topotecan hydrochloride, a pharmaceutical compound developed as a treatment for cancer, exhibits variable hydration states in a crystalline solid form chosen for manufacturing. This variability requires additional controls for successful development, and
Frederick G Vogt, Charles W Debrosse, Ann M Diederich, Gary E Zuber, Philip C Dell'orco, Jeffery L Wood, Lee M Katrincic, David J Busby, Ronald L Mueller, Qiaogong Su   +9 more
core  

Artificial Intelligence-Guided Prioritization and Experimental Evaluation of Synergistic Target Combinations for Breast Cancer Therapy. [PDF]

Pharmaceuticals (Basel)
Feng C, Feng Q, She S, Yang R, Li M, Gong L, Rui M.   +6 more
europepmc   +1 more source

Efficacy and safety of B7-H3-targeted antibody-drug conjugates in previously treated small cell lung cancer: a systematic review and meta-analysis with a contextual comparison to topotecan. [PDF]

Front Immunol
Wang J, Jiang H, Niu J, Liu L, Wu Y, Shi J, Liu L, Yin S, Feng C, Zhang L, Yang M, Yi Z.   +11 more
europepmc   +1 more source

Combination of PARPi and topoisomerase I inhibitors is highly effective in olaparib-resistant ovarian cancer. [PDF]

Exp Hematol Oncol
Chiappa M, Villa V, Sias F, Grasselli C, Sala L, Canesi S, Marabese M, Mason S, Dibitetto D, Fruscio R, Damia G.   +10 more
europepmc   +1 more source

Reversal of ABCG2-mediated MDR by VEGFR3 inhibitor (S)-SAR131675. [PDF]

Front Pharmacol
Chen X, Xu J, Li R, Dong XD, Li YD, Teng QX, Wang Z, Chen ZS.   +7 more
europepmc   +1 more source

The p53-Associated Regulation of ATF4 mRNA Expression Involves p21 and p130 in a Stress-Dependent Manner. [PDF]

Cells
Dalina A, Shilyaeva M, Kovaleva I, Chumakov P.   +3 more
europepmc   +1 more source

Decoding Small Cell Lung Cancer: Molecular Subtypes, Surface Antigens, and the Target-Modality Problem. [PDF]

Cancers (Basel)
Zambrano Iglesias MI, Rosas D, Akgun S, Padron Cubillan IC, Richani Meinhardt FW, Hussein A, Raez LE.   +6 more
europepmc   +1 more source